Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity in Patients with Ischemic CRVO

Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity

in Patients with Ischemic CRVO

Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity

in Patients with Ischemic CRVO

Fesharaki H, MD

Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity

in Patients with Ischemic CRVO

Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity

in Patients with Ischemic CRVO

Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity

in Patients with Ischemic CRVO

ﻢﺸﭼ ﻪﻠﺠﻣ ﺎﻨﻴﺑ ﻲﻜﺷﺰﭘ- ﻩﺭﻭﺩ ۱۵- ﻩﺭﺎﻤﺷ ۱) ﺰﻴﻳﺎﭘ۱۳۸۸(

ﻢﺸﭼ ﻪﻠﺠﻣ ﺎﻨﻴﺑ ﻲﻜﺷﺰﭘ- ﻩﺭﻭﺩ ۱۵- ﻩﺭﺎﻤﺷ ۱) ﺰﻴﻳﺎﭘ۱۳۸۸(

٨

Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity

in Patients with Ischemic CRVO

Razmjoo H, MD; Kian-Ersi F, MD; Moenei HA, MD; Dehghani AR, MD; Ilanloo MR, MD; Akhlaghi MR, MD;

Rismanchian A, MD; Fesharaki H, MD

Purpose: To determine the effect of intravitreal triamcinolone (IVT) injection on visual acuity in patients

with ischemic central retinal occlusion (CRVO).

Methods: This randomized clinical trial was performed on patients with ischemic CRVO referred to the

retina clinic at Feiz Hospital in 2007-2008. Inclusion criteria were: duration of CRVO less than one month,

normal IOP, no sign of diabetic retinopathy or hypertensive retinopathy, no history of laser therapy and

ocular surgery and vascular diseases. Patients were randomly allocated to two groups: intervention group

(injection of 0.1cc IVT) and control group (no injection). Follow up examinations for all patients were

scheduled 1, 2, 3 and 6 months after injection. The results were analyzed by SPSS13 and t-test.

Results: Overall, 52 patients (22 male and 30 female) entered the study. Mean age was 60.5±9.7 (range: 30-

80) years. Duration of signs was 21±5.5 days in the control group and 19±6 days in the IVT group (P= 0.66).

All patients had signs of ischemic CRVO. Mean baseline visual acuity was 1.75±0.20 logMAR in the IVT

group and 1.91±0.08 logMAR in the control group (P= 0.1). VA improvement in the IVT group was greater

in comparison with the control group at one month (P= 0.019) however this difference was not significant at

other follow-up examinations. In addition, the difference in IOP between before and after the injection was

not significant (P= 0.802).

Conclusion: This study showed that in patients with CRVO, intravitreal injection of triamcinolone, has no

significant long-term effect on visual acuity.

Key Words: Triamcinolone, Central Retinal Artery Occlusion

• Bina J Ophthalmol 2009; 15 (1): 8-12.

(PDF) Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity in Patients with Ischemic CRVO. Available from: https://www.researchgate.net/publication/320840035_Effect_of_Intravitreal_Triamcinolone_IVT_Injection_on_Visual_Acuity_in_Patients_with_Ischemic_CRVO [accessed Sep 16 2018].

ﻢﺸﭼ ﻪﻠﺠﻣ ﺎﻨﻴﺑ ﻲﻜﺷﺰﭘ- ﻩﺭﻭﺩ ۱۵- ﻩﺭﺎﻤﺷ ۱) ﺰﻴﻳﺎﭘ۱۳۸۸(

٨

Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity

in Patients with Ischemic CRVO

Razmjoo H, MD; Kian-Ersi F, MD; Moenei HA, MD; Dehghani AR, MD; Ilanloo MR, MD; Akhlaghi MR, MD;

Rismanchian A, MD; Fesharaki H, MD

Purpose: To determine the effect of intravitreal triamcinolone (IVT) injection on visual acuity in patients

with ischemic central retinal occlusion (CRVO).

Methods: This randomized clinical trial was performed on patients with ischemic CRVO referred to the

retina clinic at Feiz Hospital in 2007-2008. Inclusion criteria were: duration of CRVO less than one month,

normal IOP, no sign of diabetic retinopathy or hypertensive retinopathy, no history of laser therapy and

ocular surgery and vascular diseases. Patients were randomly allocated to two groups: intervention group

(injection of 0.1cc IVT) and control group (no injection). Follow up examinations for all patients were

scheduled 1, 2, 3 and 6 months after injection. The results were analyzed by SPSS13 and t-test.

Results: Overall, 52 patients (22 male and 30 female) entered the study. Mean age was 60.5±9.7 (range: 30-

80) years. Duration of signs was 21±5.5 days in the control group and 19±6 days in the IVT group (P= 0.66).

All patients had signs of ischemic CRVO. Mean baseline visual acuity was 1.75±0.20 logMAR in the IVT

group and 1.91±0.08 logMAR in the control group (P= 0.1). VA improvement in the IVT group was greater

in comparison with the control group at one month (P= 0.019) however this difference was not significant at

other follow-up examinations. In addition, the difference in IOP between before and after the injection was

not significant (P= 0.802).

Conclusion: This study showed that in patients with CRVO, intravitreal injection of triamcinolone, has no

significant long-term effect on visual acuity.

Key Words: Triamcinolone, Central Retinal Artery Occlusion

• Bina J Ophthalmol 2009; 15 (1): 8-12. Received: 10.5.2008 Accepted: 5.5.2009

زراﻳﺑﺎﻲ ﻖﻳرﺰﺗ ﺮﺛاﺮﺗﻳﺴﻣﺎﻴو ﻞﺧاد نﻮﻟﻮﻨﻳهﺮﺘ تﺪﺣ ﺮﺑﻲﻳﺎﻨﻴﺑﺑ ﻴ نارﺎﻤ ﻪﺑ ﻼﺘﺒﻣ

CRVO

1.

Yanoff M, Duker JS. Ophthalmology. 2th ed. St. Louis,

USA: Mosby; 2004: 862.

2.

Green WR, Chan CC, Hutchins GM, Terry JM. Central

retinal vein occlusion: a prospective histopathologic study

of 29 eyes in 28 cases. Retina 2005;25:27-55.

3.

Gass JDM. Macular dysfunction caused by retinal vascular

disease. In: Gass JDM (ed). Stereoscopic Atlas of Macular

Disease. 4th ed. St. louis, Missouri: Mosby; 1997: 437-599.

4.

Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A,

Lelong F, Samama MM. Prognostic factors for retinal vein

occlusion: prospective study of 175 cases. Ophthalmology

1996;103:551-560.

5.

Ghazi NG, Noureddine B, Haddad RS, Jurdi FA, Bashshur

ZF. Intravitreal tissue plasminogen activator in the

management of central retinal vein occlusion. Retina

2003;23:780-784.

6.

Weizer JS, Stinnett SS, Fekrat S. Radial optic neurotomy as

treatment for central retinal vein occlusion. Am J

Ophthalmol 2003;136:814-819.

7.

The central vein occlusion study group. Evaluation of grid

pattern photocoagulation for macular edema in central

vein occlusion: the central vein study group M Report.

Ophthalmology 1995;102:1425-1433.

8.

Sanborn GE, Magargal LE, Jaeger EA. Venous occlusive

disease of the retina. In: Duane's clinical ophthalmology.

Philadelphia: Lippincott Williams and Wilkins; 2004:15.

9.

Lubczyńska A, Kociecki. Inhtravitreal triamcinolone

acetonide injections in the treatment of cystoid macular

edema due to the central or branch retinal vein occlusion.

Klin Oczna 2007;109(4-6):169-72.[Article in Polish]

10.

Williamson TH, O'Donnell A. Intravitreal triamcinolone

acetonide for cystoid macular edema in nonischemic

central retinal vein occlusion. Am J Ophthalmol

2005;139:860-866.

11.

Jonas JB, Hayler JK, Söfker A, Panda-Jonas S. Regression of

neovascular iris vessels by intravitreal injection of

crystalline cortisone. J Glaucoma 2001;10:284-287.

12.

Fong DS, Segal PP, Myers F, Ferris FL, Hubbard LD, Davis

MD. Subretinal fibrosis in diabetic macular edema. ETDRS

report 23. Early Treatment Diabetic Retinopathy Study

Research Group. Arch

Ophthalmol 1997;115:873-877.

13.

Mandava N, Yannuzzi LA. Hypertensive retinopathy. In:

Regillo CD, Brown GC, Flynn HW. Jr, eds. Vitreoretinal

Disease: The Essentials. NewYork: Thieme; 1999:193-196.

14.

Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche

TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid

macular edema: an optical coherence tomography study.

Ophthalmology 2001;108:765-772.

15.

Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito

CA, Reichel E, et al. Intravitreal triamcinolone for

refractory diabetic macular edema. Ophthalmology

2002;109:920-927.

16.

Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal

injection of triamcinolone for diffuse diabetic macular

edema. Arch Ophthalmol 2003;121:57-61.

17.

Miyake K, Miyake T, Kayazawa F. Blood-aqueous barrier

in eyes with retinal vein occlusion. Ophthalmology

1992;99:906-910.

18.

Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W,

Miyamoto K, Hassessian H, et al. VEGF-initiated blood-

retinal barrier breakdown in early diabetes. Invest

Ophthalmol Vis Sci 2001;42:2408-2413.

19.

Nauck M, Karakiulakis G, Perruchoud AP,

Papakonstantinou E, Roth M. Corticosteroids inhibit the

expression of the vascular endothelial growth factor gene

in human vascular smooth muscle cells. Eur J Pharmacol

1998;341:309-315.

20.

Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit

VEGF-induced vascular leakage in a rabbit model of

blood-retinal and blood-aqueous barrier breakdown. Exp

Eye Res 2005;80:249-258.

21.

Ip M, Kahana A, Altaweel M.Treatment of central retinal

vein occlusion with triamcinolone acetonide: an optical

coherence tomography study. Semin Ophthalmol 2003;18:67-

73.

22.

Ip MS, Gottlieb JL, Kahana A, Scott IU, Altaweel MM,

Blodi BA, et al. Intravitreal triamcinolone for the treatment

of macular edema associated with central retinal vein

occlusion. Arch Ophthalmol 2004;122:1131-1136.

23.

Ramezani A, Entezari M, Moradian S, Tabatabaei H,

Kadkhodaei S. Intravitreal triamcinolone for acute central

retinal vein occlusion; a randomized clinical trial. Graefes

Arch Clin Exp Ophthalmol 2006;244:1601-1606.

24.

Bashshur ZF, Ma'luf RN, Allam S, Jurdi FA, Haddad RS,

Noureddin BN. Intravitreal triamcinolone for the

management of macular edema due to nonischemic central

retinal vein occlusion. Arch Ophthalmol 2004;122:1137-1140.

25.

Ozdek SC, Aydin B, Gürelik G, Bahçeci U, Hasanreisoğlu

B. Effects of intravitreal triamcinolone injection on macular

edema and visual prognosis in central retinal vein

occlusion. Int Ophthalmol 2005;26:27-34.

26.

Lubczyńska A, Kociecki J. Inhtravitreal triamcinolone

acetonide injections in the treatment of cystoid macular

edema due to the central or branch retinal vein occlusion.

Klin Oczna 2007;109:169-172.

27.

Gelston CD, Olson JL, Mandava N. Macular oedema in

central retinal vein occlusion treated with intravitreal

triamcinolone. Acta Ophthalmol Scand 2006;84:314-318.

28.

Patel PJ, Zaheer I, Karia N. Intravitreal triamcinolone

acetonide for macular oedema owing to retinal vein

occlusion. Eye 2008;22:60-64.

29.

Moschos MM, Brouzas D, Loukianou E, Apostolopoulos

M, Moschos M. Intraocular triamcinolone acetonide for

macular edema due to CRVO. A multifocal-ERG and OCT

study. Doc Ophthalmol 2007;114:1-7.

30.

Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal

triamcinolone acetonide and intraocular pressure. Am J

Ophthalmol 2004;138:740-743.

(PDF) Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity in Patients with Ischemic CRVO. Available from: https://www.researchgate.net/publication/320840035_Effect_of_Intravitreal_Triamcinolone_IVT_Injection_on_Visual_Acuity_in_Patients_with_Ischemic_CRVO [accessed Sep 16 2018].

https://www.researchgate.net/publication/320840035_Effect_of_Intravitreal_Triamcinolone_IVT_Injection_on_Visual_Acuity_in_Patients_with_Ischemic_CRVO